TumorBoardTuesday

@[email protected]
119 Followers
168 Following
2.8K Posts
Online Tumor Board with a molecular angle ~ Join us every Tuesday 8pm ET for discussions, polls, & mini tutorials
• Created by Dr Mike Pishvaian (@MPishvaian)
• Assisted by Alison Rothbaum (@EmpoweringPts9) & Dr John Ebben (@JohnEbbenMDPhD)
• FREE #CME
• #TumorBoard #Oncology #Oncodon #Medodon #MedMastodon #TumorBoardTuesday #PrecisionMedicine #Cancer
Twitterhttps://twitter.com/tumorboardtues
Free CMEhttps://integrityce.com/tbt2023
Facebookhttps://facebook.com/TumorBoardTues
Instagramhttps://Instagram.com/TumorBoardTues
TumorBoardTuesdayAug 2, 2023

A very complex, but thought-provoking & necessary #TumorBoardTuesday
What happens when you have a patient on biologic therapy for an autoimmune disease/#IBD & they need #BreastCancer treatment?

Weigh in!

36yo 👩🏻‍🦱 self palpates a R breast mass.
PMH: Crohn’s disease - dx 34yo, perianal fistula w/abscess, achieving remission with infliximab/AZA.
🧪Workup: T2N1 TNBC germline neg

🤨What option would you consider?

@MPishvaian @JohnEbbenMDPhD
@breastcancernow @breastcancer @tumorboard

Chemo+IO neoadj➕IO adj ​​
0%
Chemo+IO neoadj ❌IO adj
100%
Chemo❌ IO neoadj/adj
0%
🤷‍♀️ more info needed
0%
Poll ended at .
TumorBoardTuesdayAug 2, 2023
Gabriele PollaraJul 30, 2023

Very thoughtful piece on how a post-Twitter social media landscape may impact academics. Fragmentation will require some choices.

I particularly like the idea universities should embrace platforms for their networking, and not just publicity, potential.

@academicchatter #academicchatter #academia #Science #mastodon #twitter #threads #SocialMedia

https://blogs.lse.ac.uk/highereducation/2023/07/27/where-now-for-academics-on-social-media-post-twitter/

Where now for academics on social media, post Twitter? | LSE Higher Education

As Twitter enters its death spiral, there is a plethora of social media alternatives for academics to consider moving to. Mark Carrigan advises

LSE Higher Education
TumorBoardTuesdayJul 30, 2023

🌻We’re preparing #TumorBoardTuesday!

🧑‍🔬Join Dr Maryam Lustberg & Dr Adriana Kahn 08.01.23 8pm ET, for a walk through TNBC tx while pt on IS for #Crohns

🌻Don’t miss this essential MDT chat!

🧠Grab FREE #CME credits
👉🏽Visit integrityce.com/TBT2023 for more info

@JohnEbbenMDPhD @MPishvaian #OncoDon #PrecisionMedicine #Oncology #IBD #PrecisionOncology #BreastCancer #Cancer

TumorBoardTuesdayJul 24, 2023

🔥 #TumorBoardTuesday is a must-attend!

🧑‍🔬Join @marklewismd @CatherineaOC 07.25.23 8pm ET as they explore differentiating midgut & #PNETs

🔥Be part of an insightful discussion!

🧠Get FREE #CME credits as we finalize the case
👉🏽Visit integrityce.com/TBT2023 for more info #OncoDon #GastroDon

#PrecisionMedicine #Oncology #Pancreas #NETs
#NeuroendocrineTumor @MPishvaian @JohnEbbenMDPhD @EmpoweringPts9 @tumorboard @tumor

TumorBoardTuesdayMay 6, 2023

RT @TumorBoardTues
It's ALMOST time for the #TumorBoardTuesday case wrap up. We apologize for the delay, but promise it will be worth it!

Check back Saturday for our exclusive interview w @RachelRiechelm2 as we talk implications of hypermutation in #NET- don't miss it! https://twitter.com/i/web/status/1654634595868987394

#TumorBoardTuesday on Twitter

“It's ALMOST time for the #TumorBoardTuesday case wrap up. We apologize for the delay, but promise it will be worth it! Check back Saturday for our exclusive interview w @RachelRiechelm2 as we talk implications of hypermutation in #NET- don't miss it!”

Twitter
TumorBoardTuesdayMay 6, 2023

It's ALMOST time for the #TumorBoardTuesday case wrap up. We apologize for the delay, but promise it will be worth it!

Check back Saturday for our exclusive interview w @RachelRiechelm2 as we talk implications of hypermutation in #NET- don't miss it! https://twitter.com/i/web/status/1654634595868987394

#TumorBoardTuesday on Twitter

“It's ALMOST time for the #TumorBoardTuesday case wrap up. We apologize for the delay, but promise it will be worth it! Check back Saturday for our exclusive interview w @RachelRiechelm2 as we talk implications of hypermutation in #NET- don't miss it!”

Twitter
TumorBoardTuesdayMay 5, 2023

RT @TumorBoardTues
Thank you to @jessrzanotti & @RachelRiechelm2 for an exceptional #TumorBoardTuesday on hypermutation in #NET- how might this change care in the future?

Check out thread below & answer the question at the end to get free #CME!

Special edition of Case Wrap Up drops tomorrow!💡 https://twitter.com/jessrzanotti/status/1653555761094557697

Jéssica Zanotti on Twitter

“@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc 6/15 #TumorBoardTuesday 👩🏻‍🏫Mini tweetorial 2👩🏻‍🏫 📌MSI biomarker 📍≤ 10% of neuroendocrine carcinoma 📍MSI & TMB-h rare in G3 (<1%) 📍Hypermutation may be induced by temozolamide in #gliomas and #NETCancer 📍Molecular profiling upon DP on alkylating agents may find TMB-h”

Twitter
TumorBoardTuesdayMay 5, 2023

Thank you to @jessrzanotti & @RachelRiechelm2 for an exceptional #TumorBoardTuesday on hypermutation in #NET- how might this change care in the future?

Check out thread below & answer the question at the end to get free #CME!

Special edition of Case Wrap Up drops tomorrow!💡
---
RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_…
https://twitter.com/jessrzanotti/status/1653555761094557697

Jéssica Zanotti on Twitter

“@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc 6/15 #TumorBoardTuesday 👩🏻‍🏫Mini tweetorial 2👩🏻‍🏫 📌MSI biomarker 📍≤ 10% of neuroendocrine carcinoma 📍MSI & TMB-h rare in G3 (<1%) 📍Hypermutation may be induced by temozolamide in #gliomas and #NETCancer 📍Molecular profiling upon DP on alkylating agents may find TMB-h”

Twitter
TumorBoardTuesdayMay 4, 2023
RT @HannahAlison20
@chirayumohin @MPishvaian @RachelRiechelm2 @jessrzanotti @TumorBoardTues @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc @gitorrezan Making note of this. I can't wait to learn more about your findings!
TumorBoardTuesdayMay 4, 2023
RT @RachelRiechelm2
@chirayumohin @MPishvaian @jessrzanotti @TumorBoardTues @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc @gitorrezan Let’s meet! It is my agenda:)